Cargando…

Opioids for Osteoarthritis: Cross-Sectional Survey of Patient Perspectives and Satisfaction

Patients often take opioids to relieve osteoarthritis (OA) pain despite limited benefits and potential harms. This study aimed to compare cross-sectional perspectives of patients that were taking prescription opioid (N = 471) or nonopioid medications (N = 185) for OA in terms of satisfaction, expect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schnitzer, Thomas J., Robinson, Rebecca L., Viktrup, Lars, Cappelleri, Joseph C., Bushmakin, Andrew G., Tive, Leslie, Berry, Mia, Walker, Chloe, Jackson, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095440/ https://www.ncbi.nlm.nih.gov/pubmed/37048816 http://dx.doi.org/10.3390/jcm12072733

Ejemplares similares

Opioid Prescribing for Osteoarthritis: Cross-Sectional Survey among Primary Care Physicians, Rheumatologists, and Orthopaedic Surgeons
por: Schnitzer, Thomas J., et al.
Publicado: (2023)

Satisfaction with Medications Prescribed for Osteoarthritis: A Cross-Sectional Survey of Patients and Their Physicians in the United States
por: Robinson, Rebecca L., et al.
Publicado: (2022)

Factors associated with physician-reported treatment status of patients with osteoarthritis pain
por: Schnitzer, Thomas J., et al.
Publicado: (2022)

Multimodal Treatment Patterns for Osteoarthritis and Their Relationship to Patient-Reported Pain Severity: A Cross-Sectional Survey in the United States
por: Nalamachu, Srinivas R, et al.
Publicado: (2020)

Concern about addiction is associated with lower quality of life in patients with osteoarthritis: an exploratory, real-world data analysis
por: Garrison, Louis P., et al.
Publicado: (2021)

Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo‐controlled trials
por: Berenbaum, Francis, et al.
Publicado: (2021)

Response to: “Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis”
por: Tive, Leslie A., et al.
Publicado: (2018)

Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety
por: Schmelz, Martin, et al.
Publicado: (2019)

Nerve Growth Factor Signaling and Its Contribution to Pain
por: Barker, Philip A, et al.
Publicado: (2020)

Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab
por: Hunter, D.J., et al.
Publicado: (2022)

Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip
por: Tive, Leslie, et al.
Publicado: (2019)

Relationship between patient-reported disease severity in osteoarthritis and self-reported pain, function and work productivity
por: Sadosky, Alesia B, et al.
Publicado: (2010)

Burden of chronic low back pain: Association with pain severity and prescription medication use in five large European countries
por: Perrot, Serge, et al.
Publicado: (2021)

Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysis
por: Walsh, David A., et al.
Publicado: (2022)

General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo‐Controlled Trials
por: Berenbaum, Francis, et al.
Publicado: (2022)

Single and Composite Endpoints of Within-Patient Improvement in Symptoms: Pooled Tanezumab Data in Patients with Osteoarthritis
por: Schnitzer, Thomas J., et al.
Publicado: (2021)

Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis
por: Conaghan, Philip G., et al.
Publicado: (2022)

Examining the Relationships Among Treatment, Pain, and Physical Function in Patients With Osteoarthritis: A Mediation-Modeling Approach
por: Abraham, Lucy, et al.
Publicado: (2023)

Itch as Major Mediator of Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis
por: Taylor, Peter C., et al.
Publicado: (2021)

A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies
por: Callis Duffin, Kristina, et al.
Publicado: (2019)

Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes
por: Panés, Julián, et al.
Publicado: (2015)

Satisfaction with life and opioid dependence
por: Luty, Jason, et al.
Publicado: (2008)

The economic and clinical burden of early versus late initiation of celecoxib among patients with osteoarthritis
por: Shelbaya, Ahmed, et al.
Publicado: (2018)

Economic Outcomes Related to Persistence and Dosing of Celecoxib in Patients with Osteoarthritis (OA) Using a Retrospective Claims Database Analysis
por: Johnson, Courtney, et al.
Publicado: (2020)

Identification of symptom and functional domains that fibromyalgia patients would like to see improved: a cluster analysis
por: Bennett, Robert M, et al.
Publicado: (2010)

Pain and Inflammation as Mediators of Tofacitinib Treatment Effect on Fatigue in Patients with Ankylosing Spondylitis: A Mediation Analysis
por: Kristensen, Lars Erik, et al.
Publicado: (2023)

Physician and patient perceptions of surgical procedures for osteoarthritis of the knee in the United States, Europe, and Japan: results of a real-world study
por: Fukui, N, et al.
Publicado: (2022)

Quality of knee osteoarthritis care in the Netherlands: a survey on the perspective of people with osteoarthritis
por: Oomen, J. M. H., et al.
Publicado: (2022)

The handling of urinary incontinence in Danish general practices after distribution of guidelines and voiding diary reimbursement: an observational study
por: Viktrup, Lars, et al.
Publicado: (2004)

Satisfaction, Adherence and Health-Related Quality of Life with Transdermal Buprenorphine Compared with Oral Opioid Medications in the Usual Care of Osteoarthritis Pain
por: Conaghan, Philip G., et al.
Publicado: (2016)

Psychometric properties of a single-item scale to assess sleep quality among individuals with fibromyalgia
por: Cappelleri, Joseph C, et al.
Publicado: (2009)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
por: Gladman, Dafna D., et al.
Publicado: (2022)

Risk Factors Associated with Falls and Fractures Following Prescription of Opioids Among Privately Insured Patients with Osteoarthritis
por: Silverman, Stuart, et al.
Publicado: (2022)

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma
por: Cella, D, et al.
Publicado: (2012)

Relationships between changes in pain severity and other patient-reported outcomes: an analysis in patients with posttraumatic peripheral neuropathic pain
por: van Seventer, Robert, et al.
Publicado: (2011)

RETRACTED ARTICLE: Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis
por: Cella, David, et al.
Publicado: (2019)

Retraction Note to: Content validity and psychometric evaluation of functional assessment of chronic illness therapy-fatigue in patients with psoriatic arthritis
por: Cella, David, et al.
Publicado: (2019)

Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis
por: Cella, David, et al.
Publicado: (2019)

Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia
por: Brümmendorf, Tim H., et al.
Publicado: (2020)

Functional Assessment of Chronic Illness Therapy-Fatigue is a reliable and valid measure in patients with active ankylosing spondylitis
por: Cella, David, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ve7n5lr5hm8qsb1bfdpa15nrum